Item 8.01. Other Events.

On January 4, 2023, Checkpoint Therapeutics, Inc. (the "Company") issued a press release announcing the submission of a Biologics License Application to the U.S. Food and Drug Administration for the approval of cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not candidates for curative surgery or radiation.

A copy of the Company's press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



Exhibit
  No.                                  Description

  99.1     Press Release of Checkpoint Therapeutics, Inc., dated January 4,
         2023

104      Cover Page Interactive Data File (embedded within the Inline XBRL
         document)

© Edgar Online, source Glimpses